Grace Therapeutics (GRCE) Short term Debt (2019)

Grace Therapeutics has disclosed Short term Debt across 1 years of filings, most recently posting $1.4 million for Q1 2019.

• In Q1 2019, Short term Debt changed N/A year-over-year to $1.4 million; the TTM figure through Mar 2019 stood at $1.4 million (changed N/A YoY), while the FY2019 annual figure was $1.4 million, changed N/A from the prior year.
• Short term Debt came in at $1.4 million for Q1 2019 at Grace Therapeutics.
• In the past five years, Short term Debt ranged from a high of $1.4 million in Q1 2019 to a low of $1.4 million in Q1 2019.